Utilizing regulatory T cells against rheumatoid arthritis

Frontiers in Oncology

Volumn 4 JUL, Issue , 2014, Pages

  Haque, Mohammad ^a   Fino, Kristin ^a   Lei, Fengyang ^a   Xiong, Xiaofang ^a   Song, Jianxun ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CD28 ANTIGEN; CD45RA ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 6; METHOTREXATE; PROTEIN BCL XL; RAPAMYCIN; RITUXIMAB; TOCILIZUMAB; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ADALIMUMAB; CD134 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; ETANERCEPT; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 7 RECEPTOR; PADGEM PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR;

AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CELL FUNCTION; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INFLAMMATION; LYMPHOCYTE ACTIVATION; PHENOTYPE; PROTEIN EXPRESSION; STEM CELL TRANSPLANTATION; TH17 CELL; UBIQUITINATION;

EID: 84906316259     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00209     Document Type: Review

References (92)

1. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008 Nov;118(11):3537-45
2. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005 Apr 6(4):345-52
3. + regulatory T cells that express CD103. J Immunol. 2008 Oct 15;181(8):5204-8
4. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008 May 30;133(5):775-87
5. Bollyky PL, Wu RP, Falk BA, Lord JD, Long SA, Preisinger A, et al. ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors. Proc Natl Acad Sci U S A. 2011 May 10;108(19):7938-43
6. +adaptive regulatory T cells. J Immunol. 2007 Oct 15;179(8):5191-203
7. + regulatory T cells control TH17 responses in a Stat3-dependent manner. Science. 2009 Nov 13;326(5955):986-91
8. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity. 2009 May;30(5):656-65
9. Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature. 2007 Feb 15;445(7129):766-70
10. Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol. 2007 Mar;8(3):277-84
11. Kim HP, Leonard WJ. CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. J Exp Med. 2007 Jul 9;204(7):1543-51
12. + regulatory T cells. Nat Immunol. 2010 Jul;11(7):618-27
13. Yao Z, Kanno Y, Kerenyi M, Stephens G, Durant L, Watford WT, et al. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood. 2007 May 15;109(10):4368-75
14. Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A, et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6659-64
15. Duarte JH, Zelenay S, Bergman ML, Martins AC, Demengeot J. Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. European journal of immunology. 2009 Apr 39(4):948-55
16. + T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1903-8
17. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP, et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity. 2008 Jul 18;29(1):44-56
18. + Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity. 2009 Nov 20;31(5):772-86
19. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell. 2011 Sep 2;146(5):772-84
20. van der Horst A, de Vries-Smits AM, Brenkman AB, van Triest MH, van den Broek N, Colland F, et al. FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. Nature cell biology. 2006 Oct;8(10):1064-73
21. van Loosdregt J, Vercoulen Y, Guichelaar T, Gent YY, Beekman JM, van Beekum O, et al. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood. 2010 Feb 4;115(5):965-74
22. van Loosdregt J, Fleskens V, Fu J, Brenkman AB, Bekker CP, Pals CE, et al. Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cellsuppressive capacity. Immunity. 2013 Aug 22;39(2):259-71
23. + T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol. 2005 May;140(2):360-7
24. +CD25hi T-regulatory cells. Blood. 2006 Jul 1;108(1):253-61
25. Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19396-401
26. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006 Feb;24(2):179-89
27. 3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis. Nat Med. 2013 Mar;19(3):322-8
28. Coury FF, Weinblatt ME. Clinical trials to establish methotrexate as a therapy for rheumatoid arthritis. Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S9-12
29. Boyce EG, Halilovic J, Stan-Ugbene O. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-alpha inhibitor. Clin Ther. 2010 Sep;32(10):1681-703
30. De Stefano R, Frati E, Nargi F, Baldi C, Menza L, Hammoud M, et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNFalpha versus methotrexate-anti-TNF-alpha. Clin Rheumatol. 2010 May;29(5):517-24
31. Mori S, Sugimoto M. Is continuation of anti-tumor necrosis factor-alpha therapy a safe option for patients who have developed pulmonary mycobacterial infection?: Case presentation and literature review. Clin Rheumatol. 2012 Feb;31(2):203-10
32. van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexaterefractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012 May 5;379(9827):1712-20
33. Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. J Rheumatol. 2012 Feb;39(2):240-6
34. Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature. 2008 Jul 17;454(7202):350-2
35. Miossec P. Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified. Arthritis Rheum. 2007 Jul;56(7):2111-5
36. Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova FE, et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol. 2005 Jul;167(1):141-9
37. Navarro-Millan I, Singh JA, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther. 2012 Apr 34(4):788-802 e3
38. Samson M, Audia S, Janikashvili N, Ciudad M, Trad M, Fraszczak J, et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum. 2012 Aug;64(8):2499-503
39. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011 May;70(5):747-54
40. +regulatory T cell function. Science. 2008 Oct 10;322(5899):271-5
41. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 2004 Oct;21(4):589-601
42. Singh K, Gatzka M, Peters T, Borkner L, Hainzl A, Wang H, et al. Reduced CD18 levels drive regulatory T cell conversion into Th17 cells in the CD18hypo PL/J mouse model of psoriasis. J Immunol. 2013 Mar 15;190(6):2544-53
43. + T regulatory cells. J Immunol. 2005 Dec 15;175(12):7889-97
44. Gonzalez-Rey E, Gonzalez MA, Varela N, O'Valle F, Hernandez-Cortes P, Rico L, et al. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis. 2010 Jan;69(1):241-8
45. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med. 2007 Jan 22;204(1):33-9
46. +) regulatory T cells in the maintenance of immune tolerance. Front Immunol. 2012;3:165
47. Ledran MH, Krassowska A, Armstrong L, Dimmick I, Renstrom J, Lang R, et al. Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches. Cell Stem Cell. 2008 Jul 3;3(1):85-98
48. Himburg HA, Muramoto GG, Daher P, Meadows SK, Russell JL, Doan P, et al. Pleiotrophin regulates the expansion and regeneration of hematopoietic stem cells. Nat Med. 2010 Apr 16(4):475-82
49. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nature biotechnology. 2008 Jan;26(1):101-6
50. -induced pluripotency in adult neural stem cells. Cell. 2009 Feb 6;136(3):411-9
51. Li Z, Yang CS, Nakashima K, Rana TM. Small RNA-mediated regulation of iPS cell generation. EMBO Journal. 2011 Mar 2;30(5):823-34
52. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011 Jun 9;474(7350):212-5
53. Azevedo JL, Feldman RA. Tinkering with transcription factors uncovers plasticity of somatic cells. Genes & cancer. 2010 Nov;1(11):1089-99
54. Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell. 2009 Mar 6;136(5):964-77
55. Raya A, Rodriguez-Piza I, Guenechea G, Vassena R, Navarro S, Barrero MJ, et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature. 2009 Jul 2;460(7251):53-9
56. Ebert AD, Yu J, Rose FF, Jr., Mattis VB, Lorson CL, Thomson JA, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature. 2009 Jan 15;457(7227):277-80
57. Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature. 2012 Jan 19;481(7381):295-305
58. Sandhaus RA. Gene therapy meets stem cells. The New England journal of medicine. 2012 Feb 9;366(6):567-9
59. Lei F, Haque R, Weiler L, Vrana KE, Song J. T lineage differentiation from induced pluripotent stem cells. Cellular immunology. 2009;260(1):1-5
60. Lei F, Zhao B, Haque R, Xiong X, Budgeon L, Christensen ND, et al. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance. Cancer research. 2011 Jul 15;71(14):4742-7
61. Lei F, Haque R, Xiong X, Song J. Directed differentiation of induced pluripotent stem cells towards T lymphocytes. Journal of visualized experiments: JoVE. 2012 (63):e3986
62. Haque R, Lei F, Xiong X, Bian Y, Zhao B, Wu Y, et al. Programming of regulatory T cells from pluripotent stem cells and prevention of autoimmunity. J Immunol. 2012 Aug 1;189(3):1228-36
63. Schmitt TM, de Pooter RF, Gronski MA, Cho SK, Ohashi PS, Zuniga-Pflucker JC. Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nature immunology. 2004 Apr 5(4):410-7
64. 8 T cells reveal a role for notch. J Immunol. 2013 Aug 15;191(4):1704-15
65. + regulatory T-cell activation and expansion. J Allergy Clin Immunol. 2009 Apr 123(4):749-55; quiz 56-7
66. - T regulatory cells. Clin Immunol. 2009 Oct;133(1):22-6
67. Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, Ghosh T, et al. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes. 2009 Mar;58(3):652-62
68. +)CD25high regulatory T cells. Blood. 2004 Aug 1;104(3):895-903
69. + regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. J Immunol. 2005 Jul 1;175(1):32-6
70. +CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood. 2006 Dec 15;108(13):4260-7
71. + regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol. 2006 Dec 15;177(12):8338-47
72. Campbell IK, O'Donnell K, Lawlor KE, Wicks IP. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest. 2001 Jun;107(12):1519-27
73. Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol. 2002 Jan;71(1):1-8
74. Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol. 1999 Feb 1;162(3):1246-51
75. Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenen-de Roo CJ, Kolls JK, et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol. 2001 Jul 15;167(2):1004-13
76. Wright GP, Notley CA, Xue SA, Bendle GM, Holler A, Schumacher TN, et al. Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19078-83
77. Lohr J, Knoechel B, Wang JJ, Villarino AV, Abbas AK. Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med. 2006 Dec 25;203(13):2785-91
78. Jaeckel E, von Boehmer H, Manns MP. Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes. 2005 Feb;54(2):306-10
79. Qian Z, Latham KA, Whittington KB, Miller DC, Brand DD, Rosloniec EF. Engineered regulatory T cells coexpressing MHC class II:peptide complexes are efficient inhibitors of autoimmune T cell function and prevent the development of autoimmune arthritis. J Immunol. 2013 Jun 1;190(11):5382-91
80. Haque R, Lei F, Xiong X, Wu Y, Song J. FoxP3 and Bcl-xL cooperatively promote regulatory T cell persistence and prevention of arthritis development. Arthritis research & therapy. 2010;12(2):R66
81. Ruzek MC, Waire JS, Hopkins D, Lacorcia G, Sullivan J, Roberts BL, et al. Characterization of in vitro antimurine thymocyte globulin-induced regulatory T cells thatinhibit graft-versus-host disease in vivo. Blood. 2008 Feb 1;111(3):1726-34
82. Samy ET, Wheeler KM, Roper RJ, Teuscher C, Tung KS. Cutting edge: Autoimmune disease in day 3 thymectomized mice is actively controlled by endogenous diseasespecific regulatory T cells. J Immunol. 2008 Apr 1;180(7):4366-70
83. Lages CS, Suffia I, Velilla PA, Huang B, Warshaw G, Hildeman DA, et al. Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J Immunol. 2008 Aug 1;181(3):1835-48
84. Huter EN, Stummvoll GH, DiPaolo RJ, Glass DD, Shevach EM. Cutting edge: antigenspecific TGF beta-induced regulatory T cells suppress Th17-mediated autoimmune disease. J Immunol. 2008 Dec 15;181(12):8209-13
85. Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, et al. FOXP3 defines regulatory Tcells in human tumor and autoimmune disease. Cancer Res. 2009 May 1;69(9):3995-4000
86. Semitekolou M, Alissafi T, Aggelakopoulou M, Kourepini E, Kariyawasam HH, Kay AB, et al. Activin-A induces regulatory T cells that suppress T helper cell immune responsesand protect from allergic airway disease. J Exp Med. 2009 Aug 3;206(8):1769-85
87. Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol. 2010 Mar 1;184(5):2261-71
88. + T cells. Nat Immunol. 2007 Dec;8(12):1353-62
89. Ding Y, Shen S, Lino AC, Curotto de Lafaille MA, Lafaille JJ. Beta-catenin stabilizationextends regulatory T cell survival and induces anergy in nonregulatory T ells. Nat Med.2008 Feb;14(2):162-9
90. Sharabi A, Lapter S, Mozes E. Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide. J Autoimmun. 2010 Mar;34(2):87-95
91. Sharabi A, Mozes E. Bcl-xL affects the development of functional CD4 Tregs. Arthritisresearch & therapy. 2010;12(4):405
92. Wing JB, Sakaguchi S. Multiple treg suppressive modules and their adaptability. FrontImmunol. 2012;3:178